objectives Cervical cancer screening by visual inspection with acetic acid (VIA) is a widely used alternative to cytology in developing countries. This study aimed to evaluate risk factors associated with a positive VIA test and with cervical high-grade lesions on cytology.
Introduction
With more than half a million new cases and a quarter of a million deaths around the world every year, cervical cancer is a global problem [1] . This is particularly pronounced in developing countries, where approximately 85% of cervical cancer cases are diagnosed. Eastern Africa has one of the highest incidences of cervical cancer in the world, and cervical cancer is ranked as the leading cause of both female and overall cancer in the region [1] . Tanzania is one of the countries in Eastern Africa with the greatest burden of cervical cancer with an annual age-standardised incidence rate of 54 per 100 000 women in 2012. A total of 7304 women in Tanzania were diagnosed with cervical cancer in 2012, and more than 4000 died of the disease [2] .
In many developed countries, the incidence of cervical cancer has fallen in the recent decades after introduction of organised cervical cancer screening using cervical cytology [3] . In contrast, the cervical cancer incidence remains high in Tanzania and other developing countries due to lack of organised screening as well as a high prevalence of risk factors for cervical neoplasia, particularly infection with high-risk human papillomavirus (HrHPV) and human immunodeficiency virus (HIV). Persistent infection with HrHPV has been established as a necessary causal step in the development of cervical cancer [4] and the prevalence of HPV infection among East African women with normal cytology has been reported to be around 30%, which is three-fold the overall global HPV prevalence [5] . Moreover, infection with HIV increases the incidence, prevalence, persistence and progression of HPV infection [6] . In 2015, the number of HIV-positive Tanzanian women aged 15 years and older reached 780 000 [7] .
In developing countries without the necessary infrastructure and laboratory access to perform screening by cervical cytology, screening by visual inspection with acetic acid (VIA) is a widely used alternative [8] . Screening with VIA provides immediate results and allows for instant treatment if aceto-white lesions or other abnormalities are observed, which is why it is considered a simple and affordable screening test in the detection of cervical neoplasia in developing countries [9] . However, the performance of VIA in terms of sensitivity and specificity varies greatly between studies [8, 10] . The aim of the present paper was to investigate factors associated with VIA positivity and with a high-grade lesion on cytology within the same population of more than 3300 women from Tanzania, particularly to assess the impact of HrHPV and HIV infection, and to investigate the impact of other risk factors after controlling for HIV and HrHPV positivity.
Materials and methods

Study population and data collection
The study population and data collection have previously been described in detail [11] . Briefly, a cross-sectional study was conducted among women in urban and rural areas of Tanzania from February 2008 to March 2009. The urban population consisted of women living in urban (Dar es Salaam Region) and semi-urban areas. In Dar es Salaam Region, women were recruited consecutively from the Ocean Road Cancer Institute (ORCI) screening clinic where they came for screening following public announcements via media, radio and public notice/placard. Women from the community-based group were invited to meet at their nearest hospital or health centre for an interview and a gynaecological examination. The rural population consisted of women residing in Pwani (northeast and southeast of the Dar es Salaam Region), Mwanza (northwestern Tanzania), and Mtwara (southeastern Tanzania), where cervical cancer screening clinics were set up in small district hospitals and health centres.
General public announcements informed women that cervical screening was taking place and encouraged them to meet at their nearest hospital or health centre for an interview and a gynaecological examination. All participants were interviewed by trained female nurses using a structured questionnaire. The gynaecological examination was performed by trained nurses and included VIA, a conventional Pap smear, and collection of cervical cells for later HPV testing. In addition, a blood sample was obtained for HIV testing. All women were given oral information about the study and informed consent was obtained from all women before their inclusion in the study. The study was approved by the ethical committee of the Tanzanian National Institute of Medical Research.
Cervical cytology
Cervical cells were collected using an Aylesbury wooden spatula (CellPath, Wales, United Kingdom) and endocervical brush (CellPath, Wales, UK), smeared on a glass slide and fixed in ethanol. After fixation, slides were air dried and stored in glass slide plastic containers. Subsequently, the slides were sent to the Department of Pathology, Hvidovre University Hospital, Denmark, where cervical cytology samples were stained and examined and classified according to the Bethesda classification system [12] . No information concerning the study participants was revealed to the pathology personnel.
HPV testing
The method used to test for the presence of HrHPV DNA in the cervical samples has been described previously [13] . Briefly, the cervical samples for HPV testing were collected in sample transport media (Digene Corporation, Gaithersburg, MD), stored at À20°C and shipped at the end of the study to the Division of Experimental Virology, University Hospital of T€ ubingen, Germany, for HPV testing. Laboratory personnel were blinded to the data associated with the samples. The testing was done by the Hybrid Capture 2 method (HC2; Qiagen, Hildesheim, Germany), which detects at least 13 HrHPV types (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59 and 68) [14] . Samples attaining ≥1.0 pg/ml of HPV DNA were considered positive. HPV DNA was isolated in the HC2 positive cervical samples and analysed in a line blot assay based on the principle of reverse hybridisation (LiPaExtra; Innogenetics, Gent, Belgium) to determine the HPV genotype. This test covers all currently known HrHPV and probable HrHPV types (16, 18, 26, 31, 33, 35, 39, 45 , 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) as well as seven low-risk types (6, 11, 40, 43, 44 , 54 and 70) and three additional types (69, 71 and 74) [14] . The participants were unaware of the HPV results obtained in the present study, and the results were not used for further management or treatment of the women.
Visual inspection with acetic acid (VIA)
In 2002, WHO and the International Agency for Research on Cancer (IARC) assisted ORCI in implementing a cancer screening programme based on VIA for the detection of precancerous lesions. From 2005-2009, a WHO/IARC demonstration project was conducted in six African countries, including Tanzania, to prevent cervical cancer through screening using VIA. Local training was conducted by clinicians who were experienced in VIA and cryotherapy and supportive supervision and refresher training was conducted at regular intervals by the country project coordinators. In our study, the programme was first initiated at ORCI and subsequently extended to hospitals and health centres at district level. In each new location, at least two health care personnel had attended a cervical cancer training programme organised by ORCI/IARC within the past 12 months [9, 10] . VIA was performed following the collection of cervical cells for cytology and HPV DNA detection. A 5% acetic acid solution was applied on the cervix using a cotton-tipped swab. The VIA result was considered positive when welldefined distinct aceto-white areas appeared close to the squamocolumnar junction within one minute after application of acetic acid [8] .
HIV testing
The blood samples were tested for HIV in accordance with Tanzanian Ministry of Health guidelines using the following algorithm. The first test used was a rapid immunoassay (SD Bioline HIV-1/2 3.0 rapid test, Standard Diagnostics Inc., South Korea), and if positive, this was followed by a confirmatory immunologic test (Determine HIV-1/2, Abbott Laboratories SA, South Africa). In case of discrepancy between the two tests, a third test was used (UNIGold method/Recombigen HIV, Trinity Biotech, NY, USA). When tested, women were given preand post-HIV test counselling by a trained nurse. HIVpositive women were referred to Care and Treatment Clinics, where they were offered thorough clinical followup and treatment.
Statistical analysis
We investigated risk factors for VIA positivity and for high-grade cytological abnormalities (high-grade squamous intraepithelial lesions (HSIL) or worse (carcinoma-in situ and cervical cancer) separately. The associations between these two outcomes and potential risk factors were expressed as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). The variables included for analysis were selected a priori, based on the literature and the availability in the questionnaire. They included socio-demographic factors (age and educational level), reproductive and sexual behaviour (number of births and lifetime number of partners), and medical conditions (HrHPV status, HIV status and body mass index (BMI)). Age and lifetime number of partners were included as both categorical and continuous variables, whereas the others were included as categorical variables only. First, the variables were analysed in a bivariate model adjusted for age as a continuous variable. Next, a multivariable logistic regression analysis was performed where we, in addition, adjusted for HrHPV and HIV, which were selected a priori. Missing values were excluded in the analyses. Statistical significance was considered at P < 0.05 and all statistical tests were twosided. All statistical analyses were carried out using SAS Enterprise Guide, version 5.1.
Results
A total of 3699 women were enrolled in the study after exclusion of 37 women with clinical conditions that prevented a proper examination (e.g. total hysterectomy, menstruation and pregnancy) and 31 women with incomplete samples for HPV testing (lacking or insufficient cell material). Furthermore, 96 women were excluded due to inadequate or missing Pap smear results and 264 women because of no HIV testing, leaving 3339 women for analysis (Figure 1 ). At enrolment, the women were 15-82 years of age with a mean age of 38 years. About half of the women (50.4%) lived in urban areas and half (49.6%) in rural areas. A percentage of 63.4% had completed primary school, 24.3% had completed secondary school or university, while the remaining 12.3% had no formal education. A percentage of 50.0% of women were overweight (BMI ≥ 25.0) and 4.9% were underweight (BMI < 18.5). Approximately one-third (32.0%) reported one lifetime partner, 27.8% had 3-4 partners and 15.7% reported to have had five or more sexual partners. None reported to be virgins. Most of the women (87.3%) had given birth, with the majority (32.4%) reporting one or two births. The overall prevalence of HrHPV was 20.1% (37.9% among VIA-positive women and 94.4% among women with high-grade cytology). The overall prevalence of HIV was 10.0% (29.7% among VIA-positive women and 22.6% among women with high-grade cytology).
The cervical examinations identified 145 (4.3%) VIApositive women. Table 1 presents risk factors for VIA positivity. The mean age was the same (38 years) among VIA-negative and VIA-positive women and no association between age and VIA positivity was found. Odds for being VIA-positive (OR = 0.69; 95% CI: 0.49-0.99) were lower among overweight than normal weight women. There was an almost two-fold increased risk of being VIA-positive in HrHPV-positive vs. HrHPV-negative women (OR = 1.97; 95% CI: 1.37-2.85). HIV-positive women were more than three times more like to be VIApositive than HIV-negative women (OR = 3.48; 95% CI: 2.34-5.17). No association was found between lifetime number of partners, number of births, or educational level and risk of VIA positivity.
The cytology results showed that 3002 (89.9%) women had normal cytology whereas 337 (10.1%) had abnormal cytology with 213 (6.4%) women having low-grade cytology and 124 (3.7%) having high-grade cytology. Risk factors for high-grade cytology vs. cytology negative women are presented in Table 2 . The mean age among women with normal cytology was 38 years, while women with highgrade lesions had a mean age of 43 years. The risk of highgrade cytology increased significantly with age, with an increase in odds of 6% (OR = 1.06; 95% CI: 1.04-1.08) per each additional year. Women who had given birth to five or more children had an almost four-fold increased risk of high-grade lesions compared with nulliparous women (OR = 3.91; 95% CI: 1.40-10.94). Furthermore, the odds of high-grade cytology were higher in underweight compared with normal weight women (OR = 2.94; 95% CI: 1.31-6.59). HrHPV-positive women had a more than 100-fold increased risk of high-grade lesions compared with HrHPV-negative women (OR = 110.1; 95% CI: 50.4-240.4). Being HIV-positive increased the odds of high-grade cytology in the age-adjusted analysis (OR = 3.44; 95% CI: 2.20-5.38), but this effect was no longer apparent when additional adjustment for HrHPV was performed (OR = 1.27; 95% CI: 0.78-2.08). Likewise, an increased risk of high-grade lesions was observed in women with no formal education (OR = 2.11; 95% CI: 1.09-4.08) and primary school (OR = 1.99; 95% CI: 1.17-3.38) vs. women with secondary school/university only in the age-adjusted analysis. There was no association between lifetime number of partners and risk of high-grade lesions after adjustment for age, HrHPV and HIV.
In a sub-analysis with additional adjustment for number of births and BMI, the associations remained virtually unchanged (data not shown).
Discussion
In this cross-sectional study among more than 3300 Tanzanian women, both HrHPV and HIV were associated with VIA positivity, while only HrHPV and not HIV remained a major risk factor for high-grade cytology after mutual adjustment for age, HrHPV and HIV. To our knowledge, no previous study on predictors of VIA positivity has assessed the mutually adjusted effect of HrHPV and HIV. In accordance with our findings, some recent cross-sectional studies from developing African countries have reported increased risk of VIA positivity among HIV-positive women [15, 16] . Only few studies have assessed HrHPV as a risk factor for VIA positivity. In agreement with our results, some report significantly increased risk [17, 18] , while others found a non-significant decreased risk in HPV-positive compared with HPV-negative women [19] . A prospective cohort study conducted in rural China found that VIA positivity was influenced by testing HPV-positive with a high viral load (>100 rlu/pc which is equal to 100 pg/ml) [17] .
The prevalence of HrHPV is generally found to be higher among HIV-positive women and has been proposed as a potential explanation for the association between HIV and VIA positivity [15] . Some studies find an association between HIV and HPV prevalence and this relationship could indicate both a greater susceptibility to HPV among HIV-positive women, possibly due to immunosuppression, and an increased risk of HIV acquisition among HPV-positive individuals [6, 20] . In the present study, where we take both factors into account, we VIA, visual inspection with acetic acid; OR, odds ratio; CI, confidence interval; BMI, body mass index; HrHPV, high-risk human papillomavirus; HIV, human immunodeficiency virus. *Adjusted for age (continuous). †Adjusted for age (continuous), HrHPV and HIV.
find that both HPV and HIV infection are risk factors for VIA positivity after mutual adjustment. After adjustment for both HrHPV and HIV, we still found a reduced risk of VIA positivity among overweight women, which may be explained by difficulties in performing VIA on overweight women. We are not aware of any prior reports on the association between BMI and VIA positivity.
We found no association between VIA positivity and age. Results from previous studies on the association between age and VIA positivity are inconsistent; some have found a higher risk of VIA positivity with increasing age [19, 21] , while others report the opposite or no association [22, 23] . Finally, in line with some others, lifetime number of partners [22] and education [8] were not significantly associated with VIA positivity in our study, whereas other studies found that increasing number of lifetime partners [23] and a low educational level [21, 23] increased the likelihood of a positive VIA test.
The overall VIA positivity rate among the women in our study was 4.3%. VIA positivity rates reported by other cross-sectional studies in developing countries range from 4% to 16% [9, 16, 22, 24] , which makes the prevalence found in our study among the lowest observed in African women. The variability across studies may be due to other factors than disease prevalence. Thus, results of visual tests such as VIA may reflect subjectivity among the staff performing the test owing to different levels of experience, training and supervision. Furthermore, varying standards for disease definition and differences in the characteristics of the screened population (i.e. prevalence of HIV, HPV and other sexually transmitted diseases) [25] may also explain heterogeneity in VIA-positive rates across studies. These considerations should be taken into account in the interpretation of the VIA positivity rate found in this study. We found a more than 100-fold increased risk of highgrade cytology in HrHPV-positive women compared with HrHPV-negative women. Interestingly, the increased odds of high-grade lesions in HIV-positive women in the ageadjusted model were no longer apparent upon additional adjustment for HrHPV. Thus, the risk of high-grade cytology appears to be primarily associated with HPV infection. Similar results have been reported in a crosssectional [26] and a prospective study [27] . In contrast, another cross-sectional study among female sex workers found a significantly increased risk of HSIL in HIV-1-positive women, while the association between HrHPV and HSIL was weak and non-significant [28] . Previous cross-sectional studies examining only HIV-positive women also found infection with HrHPV to be an independent predictor of high-grade cytology [29, 30] .
The risk of having high-grade lesions in our study also increased significantly with age as well as with increasing parity after adjustment for HrHPV and HIV. Some previous studies found no statistically significant association between age and parity and high-grade cytology [28, 31] whereas others also found an increased risk for highgrade cytology among multiparous women [32] . It has been suggested that this increase could be due to influences of endogenous hormones or altered immune status. Our finding of underweight women having a greater risk of high-grade cytology has to our knowledge not been reported previously but could represent a poorer nutritional and general health status resulting in a compromised immune response towards HPV and thereby an increased risk of high-grade lesions on the cervix.
Among the women enrolled in our study, 4% had highgrade cytology. As with VIA positivity rates, comparison with other studies is difficult due to variations in study populations such as, for example, age distribution and previous screening. A similar prevalence of high-grade cytology has been reported in screening studies among healthy Congolese and Kenyan women enrolled through health centres independently of HIV status [26, 33] .
We found differences in the roles of HrHPV and HIV as risk factors for VIA positivity and high-grade cytology, respectively. Considering that HPV infection has been established as a necessary cause of cervical cancer, the limited contribution of HrHPV to the risk of VIA positivity found in our study may raise concern of using VIA as the sole method of screening. We observed a strong impact of HrHPV on the risk of high-grade cytology, which underlines the potential of using HPV testing as a cervical screening tool in developing countries. A large community-based randomised trial in rural India has shown significant reductions in the rate of advanced cervical cancers and associated deaths after a single round of HPV screening [34] . A robust and affordable HPV test, which does not need laboratory access, has been proposed as a primary screening method in low-resource regions [35] .
The main strength of this study is the large sample size of both urban and rural Tanzanian women covering a wide age range. Information on BMI (height and weight) was obtained by study personnel to ensure the accuracy of the data. Some important limitations should also be mentioned. The women in the study had a higher educational level than the general female population in Tanzania. Even though we aimed at including women from different geographical and socio-demographic areas and neighbourhoods of Tanzania, potential selection bias is a limitation of this study and therefore the results may not be entirely generalisable to all women in Tanzania. Self-reporting of information on topics as sexual habits and risk-taking behaviour may result in recall or social desirability bias. Despite the large sample size, the number of women with positive VIA and high-grade cytology was still relatively limited. We were not able to validate the VIA or cytological results with histological examination of biopsies, which limits the comparability with studies reporting on risk factors for histological diagnoses. Finally, the crosssectional nature of the study prevents us from assessing the temporality of HPV and HIV acquisition.
In conclusion, HrHPV and HIV were risk factors for VIA positivity. Higher BMI reduced the risk for VIA positivity. HrHPV was the major risk factor for high-grade cytology among Tanzanian women. Low BMI and multiparity were independent risk factors for high-grade cytology. Further assessment of cervical cancer screening possibilities in developing countries is necessary and studies assessing the implementation of alternative screening tests such as HPV testing will be of great value.
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